Full text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Robot-assisted therapy (RAT) is a promising area of translational neuroscience for children with autism spectrum disorders (ASDs). It has been widely demonstrated that this kind of advanced technological tool provides a reliable and efficient intervention for promoting social skills and communication in children with ASD. This type of treatment consists of a human-assisted social robot acting as an intervention mediator to increase competence and skills in children with ASD. Several social robots have been validated in the literature; however, an explicit technical comparison among devices has never been performed. For this reason, in this article, we provide an overview of the main commercial humanoid robots employed for ASD children with an emphasis on indications for use, pitfalls to be avoided, and recent advances. We conclude that, in the near future, a new generation of devices with high levels of mobility, availability, safety, and acceptability should be designed for improving the complex triadic interaction among teachers, children, and robots.

Details

Title
Social Humanoid Robots for Children with Autism Spectrum Disorders: A Review of Modalities, Indications, and Pitfalls
Author
Puglisi, Alfio 1 ; Caprì, Tindara 2 ; Pignolo, Loris 3   VIAFID ORCID Logo  ; Gismondo, Stefania 1 ; Chilà, Paola 1 ; Minutoli, Roberta 1 ; Marino, Flavia 1 ; Failla, Chiara 1 ; Arnao, Antonino Andrea 1 ; Tartarisco, Gennaro 1   VIAFID ORCID Logo  ; Cerasa, Antonio 4 ; Pioggia, Giovanni 1   VIAFID ORCID Logo 

 Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy; [email protected] (A.P.); [email protected] (T.C.); [email protected] (S.G.); [email protected] (P.C.); [email protected] (R.M.); [email protected] (F.M.); [email protected] (C.F.); [email protected] (A.A.A.); [email protected] (G.T.); [email protected] (G.P.) 
 Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy; [email protected] (A.P.); [email protected] (T.C.); [email protected] (S.G.); [email protected] (P.C.); [email protected] (R.M.); [email protected] (F.M.); [email protected] (C.F.); [email protected] (A.A.A.); [email protected] (G.T.); [email protected] (G.P.); Department of Life and Health Sciences, Link Campus University, Via del Casale di S. Pio V, 44, 00165 Rome, Italy 
 S’Anna Institute, 88900 Crotone, Italy; [email protected] 
 Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), 98164 Messina, Italy; [email protected] (A.P.); [email protected] (T.C.); [email protected] (S.G.); [email protected] (P.C.); [email protected] (R.M.); [email protected] (F.M.); [email protected] (C.F.); [email protected] (A.A.A.); [email protected] (G.T.); [email protected] (G.P.); S’Anna Institute, 88900 Crotone, Italy; [email protected]; Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health Science and Nutrition, University of Calabria, 87036 Arcavacata, Italy 
First page
953
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
22279067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2693952832
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.